The aim of the present study was to characterize a patient-derived in vitro 3D model KRAS mutations were detected in 58% of the parental tumours, and a significantly higher growth rate was observed for tumoroids established from the KRAS-mutated tumours compared to wild-type tumours (P < 0.0001). The average relative growth rate (log10) on day 10 was 0.360 ± 0.180 (mean ± SD) for the KRAS-mutated group and 0.098 ± 0.135 (mean ± SD) for the KRAS wild-type group. These results showed that the presence of KRAS mutations in parental tumours is associated with an acceleration of the growth rate of tumoroids. The future perspective for such a model could be the implementation of chemoassays for personalized medicine.
| INTRODUCTION
Over the past decade, three-dimensional cultures of cancer cells (tumoroids) have proven to be an important tool in personalized medicine and in vitro investigations of tumours. 1, 2 It has been demonstrated that tumoroids can be established in vitro with a high success rate. 3, 4 Tumoroids resemble their parental tissue more closely than monolayer cultures, since original cell-cell and cell-matrix attachments are maintained during tumoroid formation. 3, 5, 6 This similarity is attributed to a major presence of cells positive for epithelial cell adhesion molecules (EpCAM) in tumoroids established from colorectal cancer (CRC). 3, 5 Therefore, tumoroids are good candidates in experimental modelling of tumour functionality, disease pathogenesis and therapy response. 7, 8 In the present study, tumoroids have been characterized by their growth rate and whether the presence of Kirsten rat sarcoma (KRAS) mutation in the parental tumour has any effect on the growth rate. More than 70% of colorectal adenocarcinomas show at least one genetic dysregulation in the MAPK/PI3K signalling pathway. 9 KRAS protein contributes to the transmission of extracellular growth signals into the nucleus, resulting in increased cellular growth and mitotic activity. 10 It has been shown in animal models that KRAS mutations stimulate proliferation of colon epithelial cells.
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KRAS mutations are one of the most common types of mutations in CRC. 11 Point mutations in exon 2 (codons 12 and 13) are the most prevalent types of mutations in the KRAS gene. 12, 13 Mutations in KRAS exon 2 codon 13
have been shown to be associated with poor prognosis, 12 whereas mutations in KRAS exon 2 codon 12 are associated with lymph node metastasis and advanced stages of disease.
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The hyperproliferation of KRAS-mutated tumours can be attributed to upregulation of the surface receptors involved in MAPK/PI3K signalling pathway. These receptors include but not limited to epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR). [14] [15] [16] The aim of the present study was to investigate whether the parental KRAS status of the tumoroids has a prolonged effect on the growth rate of the tumoroids. For this purpose, the status of KRAS in the parental tumour was determined and the presence of mutations was correlated with the in vitro growth rate of tumoroids. 
| MATERIALS AND METHODS

| Tumour samples
| Ethical approval
The study protocol was approved by the Science Ethics Committee of The Capital Region of Denmark (No. H-1-2011-125).
| In vitro 3D cultures
Tumoroids were cultured based on the work by Jeppesen et al 17 Tumour specimens were cut into 1-2 mm 2 fragments using an ordinary scalpel while keeping the tissue on ice. Tumour fragments were washed with cold DPBS and dissociated partially by 1 mg/mL collagenase type II (Thermo Fisher Scientific) in DPBS at 37°C in several steps. The dissociated fragments were serially filtered to reach a size of 30-70 μm. These fragments were transferred to a 10-cm Petri dish containing stem cell medium (StemPro hESC SFM, Thermo Fisher Scientific) coated with 1.5% agarose (Sigma-Aldrich) by rinsing the filter remnants with 2 mL of StemPro hESC medium (Thermo Fisher Scientific) supplemented with 200 U/mL penicillin, 200 U/mL streptomycin (Sigma-Aldrich), 200 μg/mL gentamicin (Thermo Fisher Scientific) and 2.5 μg/mL amphotericin B. The Petri dishes were transferred to a 37°C humidified incubator with 5% CO 2 and were monitored daily by light microscopy for the formation of tumoroids. Following the formation of tumoroids (integrated and round structures with smooth surface), debris and individual cells were removed by DPBS rinsing and filtered to select tumoroids of 70-100 μm in diameter. Approximately 15 tumoroids per well were seeded in a 384-well low volume, non-treated microtiter plate (Corning Life Sciences, Tewksbury, Massachusetts, USA) containing 1:2 mixture of stem cell medium with Matrigel (Corning Life Sciences).
| Growth monitoring of tumoroids
Tumoroids were cultured in a 37°C humidified incubator with 5% CO 2 for 11 days. Microscopy images of the wells were recorded by oCelloScope ™ (BioSense Solutions, Farum, Denmark). The growth rate of tumoroids was reported as the total area of tumoroids, defined as regions of interest in each well, relative to the area at day 0. As
described by Fredborg et al, 18 the oCelloScope ™ is a fluidsamples microscopy technology using tilted imaging planes for 3D image acquisition. By combining the tilted images, a single z-plane is generated. Focus was set automatically in two equal halves of each well, and subsequently, the recorded images were stitched together. Image processing and analysis were performed using algorithms developed by 2cureX.
| Targeted mutations
The single-nucleotide polymorphisms on codons 12, 13, 58, 59, 61, 117 and 146 of the KRAS oncogene were investigated in formalin-fixed, paraffin-embedded samples of the original tumours. The appropriate section for molecular analysis was selected by microscopy of haematoxylin and eosin-stained sections following these criteria in each tissue block: more than 400 malignant cells, more than 70% tumour proportion and less than 5% necrosis. 
| RESULTS
Tumoroids were successfully established from all 26 patients with primary colorectal adenocarcinoma or from liver metastasis of colorectal adenocarcinoma. The histology of the tumoroids demonstrated glandular structures that resembled the histological structure of colorectal epithelium. Furthermore, the high nuclear-cytoplasmic ratio of the cells in the tumoroids indicates the hyperproliferative feature of the tumoroids ( Figure 1A-C) . None of the liver metastasis samples were from the same patients as the primary tumours. All the tumours were histologically diagnosed as glandular adenocarcinoma. The clinical characteristics of the tumours are summarized in Table 1 . The age of the patients varied from 52 to 85 years old with an average of 70.2 years (± 8.7, SD).
F I G U R E 1
| KRAS mutations in the parental tumours enhanced growth rate of tumoroids established from colorectal adenocarcinomas
The tumoroids were categorized into those established from KRAS wild-type parental tumours and those from KRAS-mutated parental tumours. The KRAS mutations were detected in 58% of the parental tumours. The investigated subtypes of KRAS mutations included G12D, G13D, A146T, G12V, G12S and G12-G13insG (Table 1 ). The average relative growth rate (log10) for tumoroids differed for each patient (Figure 2) . Overall, the growth rate on day 10 was 0.360 ± 0.180 (mean ± SD) for the KRAS-mutated group and 0.098 ± 0.135 (mean ± SD) for the KRAS wildtype group. The linear regression analysis with mixed effects on the whole period of cultures from day 1 to day 11 showed that the log10 relative growth rate of tumoroids in the KRAS-mutated group was significantly higher than the growth rate for tumoroids in the KRAS wild-type group (P < 0.0001). Figure 2 shows that the growth rate of tumoroids in the KRAS-mutated and in the wild-type group differed from day 7. Subtypes of KRAS mutation in the parental tumours did not show any significant effect on the relative growth rate of tumoroids established from these tumours (Table S1) . Table S2 shows distribution of KRAS mutations correlated to staging of the primary tumours. The stage of primary parental tumours was not correlated to the growth rate of tumoroids.
| DISCUSSION
Our group has previously shown that tumoroids established from colorectal adenocarcinoma consisted almost purely of the EpCAM-positive epithelial cells with very little fibroblast contamination. These results have shown that the cellular composition of the tumoroids reflects the variation in cellular composition of the parental tumours. Furthermore, the average expression of cytokeratin 20 and carcinoembryonic antigen (CEA) in the tumoroids was comparable to the expression rate of these markers in the parental tumours and remained unchanged over a 10-day period in the culture. 17 The hallmarks of cancer biology presented by Hanahan and Weinberg show that different factors in the tumour microenvironment play significant roles in tumour development and progression. 21 One of these hallmarks is the hyperproliferative character of the invasive tumours. The KRAS mutation makes tumours prone to such a hyperproliferative state. 10 In the present study, the prolonged effect of the parental KRAS status on growth rate of the tumoroids was investigated. The incidence of KRAS mutations in primary tumours was 58%, which is similar to previous reports. 9, [22] [23] [24] The previous studies on KRAS-mutated mouse models showed significantly more proliferative cells in the bottom of colonic crypts 10 and significantly higher tumour size than non-mutated models. 25 The present study showed that tumoroids established from tumours with KRAS mutations grew faster than tumoroids established from KRAS wild-type tumours.
The most frequent alterations in the KRAS are G > A transition as well as G > T and G > C transversions in codon 12 and codon 13.
9, 26 Haigis et al 10 have shown that expression of the G12D subtype of KRAS in engineered mice stimulates hyperproliferation of colon epithelium. Furthermore, Collado et al 27 showed in a mouse model that activating KRAS mutation triggers development of adenocarcinomas. This study showed that the KRAS status in the parental tumour functionally influences the in vitro growth rate of tumoroids. To the best of our knowledge, this is the first study to demonstrate that in vitro patient-derived 3D tumoroid cultures of CRC with KRAS mutations in their parental tumours grow faster than tumoroids established from KRAS wild-type tumours.
The results of this study show that patient-derived tumoroids originated from CRC grow in laboratory conditions and that automated image analysis can be implemented to monitor their growth rate. This model can be implemented in highthroughput assays to study the in vitro growth of solid tumours. Furthermore, this in vitro model may be used in chemoassays in relation to personalized medicine. In such an assay, different combinations of chemotherapeutic agents can be tested in laboratory conditions prior to the selection of chemotherapy regimen. This tool can help oncologists choose the most effective chemotherapy regimen with the minimum side effects.
In summary, the present study characterized the in vitro growth of the patient-derived tumoroids established from colorectal adenocarcinoma. The results showed that KRAS mutations in the parental tumour correlate with higher growth rate of tumoroids in vitro. The specific subtypes of KRAS mutation did not show any different growth rate. These findings shed light on an important factor affecting the in vitro model of patient-derived tumoroids from colorectal adenocarcinoma. The future perspectives for this model could be the implementation of chemo-screening assays for personalized chemotherapy or investigations of different functional aspects of the solid tumours.
